Concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas. Preliminary results of a phase II, single-institutional trial
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
This study aims to asses the effectiveness and toxicity of boost radiotherapy concomitant and concurrent cisplatin for patients with locally-advanced head and neck cancer (LAHNC).
Material and methods
There were 30 patients included in a prospective, phase II single-institution trial and of whom, 29 were at AJCC stage IV and 1 at stage III. Treatment consisted of radiotherapy-acceleration fractionation with concomitant boost, 72 Gy, and 2 cycles of concomitant cisplatin (20 mg/m2/day continuous infusion; days 1–5 and 29–33). Amifostine, (i.v. 200 mg/m2) was administered to 26 prior to the first fraction of radiotherapy. Endpoints of the study were quality-of-life (QL), overall survival, and local control of disease.
Complete response (CR) was achievedin 23 patients (77%), 2 patients had partial response (PR) (7%), 4 had no response (13%), and 1 was not evaluated for response. The 2-year overall survival and loco-regional control were 60% and 56%, respectively. Main toxicity was grade 3 or 4 mucositis in 93% of the patients. QL scores (questionnaire QLQ-C30; version 3.0) and the HN cancer module QLQ-HN35) showed a worsening in areas related to the treatment e.g. dry mouth, problems stretching the mouth, and sticky saliva.
this combination modality is active, but toxic, in the treatment for LAHNC. Concomitant boost radiotherapy is probably, not the best radiotherapy schema for combining with chemotherapy in LAHNC.
- Vokes EE, Weichselbaum RR, Lippman S, et al. Head and neck cancer N Engl J Med. 1993;328:184–94. CrossRef
- Paccagnell A, Orlando A, Marcniori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui tumori della Testa e del collo. J Natl Cancer Inst. 1994; 86:265–72. CrossRef
- Jacobs C, Makuch R. Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: A subset analysis of the Head and Neck Contracts Program. J Clin Oncol. 1990;18:838–47.
- Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. Engl J Med. 1993;328:15–20. CrossRef
- Fletcher G, Lindberg R, Hamberger H, et al. Reasons for irradiation failure in squamous cell carcinoma of the larynx. Laryngoscope. 1975;85:987–92. CrossRef
- Withers HR. Biologic basis for alterated fractionation schemes. Cancer. 1985;55:2086–96. CrossRef
- Ang KK, Peter LJ, Webwe RS, et al. Concomitant boost radiotherapy schedules in the treatment of the carcinomas of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys. 1990;19:1339–45.
- Dische S, Saunders MI. The rationale for continuous, hyperfractionated, accelerated radiotherapy (CHART). Int Radiat Oncol Biol Phys. 1990;19:1317–20.
- Horiot JC, Le Fur R, N’Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC Cooperative Group of Radiotherapy. Radiother Oncol. 1990;8:838–47.
- Fu KK, Pajak F, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation therapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;7–16.
- Pignon JP, Bourhis J, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949–55.
- Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent lowdose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol. 2000;18:1458–64.
- Adelstein DJ, Li Y, Adams GL, et al. Comparison os standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92–8. CrossRef
- Vokes EE, Weichselbaum RR. Concomitant chemoradiotherapy: Rationale and clinical experience in patients with solid tumors. Clin Oncol. 1990;8:911–34.
- Adelstein DJ, Saxton JP, Lavertu P, et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results. Head & Neck. 1887;19:567–75. CrossRef
- Browman GP, Cripps C, Hodson DI, et al. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol. 1994;12:2648–53.
- Haffty BG, Son YH, Papac R, et al. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: Results of the Yale Mitomycin Randomized Trials. J Clin Oncol. 1997;15: 268–76.
- Merlano M, Benasso M, Corvo R, et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 1996;88:583–9. CrossRef
- Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol. 1998;16:1318–24.
- Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798–804. CrossRef
- Al-Sarraf M, LeBlanc M, Giri PGS, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099. J Clin Oncol. 1998;16:1310–7.
- Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst. 1999;2081–6.
- Miller AB, Hoogstraten B, Staquet, et al. Reporting results of cancer treatment. Cancer. 1981;47:207–14. CrossRef
- Rubin P, Constine LS, Fajardo L, Phillips T, Wasserman T. Overview: Late Effects of Normal Tissues (LENT) Scoring System. Int J Radiat Oncol Biol Phys. 1995;31:1041–2. CrossRef
- Abitbol AA, Schawade JG, Lewin AA. Hyperfractionated radiation therapy and concurrent 5-fluorouracil, cisplatin and mytomicin-C in head and neck carcinoma. Am J Clin Oncol. 1992;15:250–5. CrossRef
- Choi KN, Rotman M, Aziz H, et al. Locally advanced paranasal sinus and nasopharynx tumors treated with hiperfactionated radiation and concomitant infusion cisplatin. Cancer. 1991;67:2748–52. CrossRef
- Fontanesi J, Beckford NS, Lester EP, et al. Concomitant cisplatin and hyperfractionated external beam irradiation for advanced malignancy of the head and neck. Ann J Surg. 1991;162:393–6. CrossRef
- Glanzmann C, Lutolf UM. Follow up data of our pilot study on concomitant hyperfractionated radiotherapy and cisplatinum (CDDP) in patients with advanced cancer of the head and neck. Strahlenther Onkol. 1992; 168:453–6.
- Harrison LB, Pfister DG, Shah JP, et al. Concomitant chemo-radiation therapy for advanced unresectable head and neck cancer. Int J Radiat Oncol Biol Phys. 1991; 21:703–8.
- Vokes EE, Kies MS, Haraf DJ, et al. Concomitant chemoradiotherapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000;18:1652–61.
- Adelstein DJ, Saxton JP, Lavertu P, et al. Maximixing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol. 2002;20:1405–10. CrossRef
- Forastiere AA, Bellibeau JF, Goren MO, et al. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum (II) in head and neck cancer patients. Cancer Res. 1988;48:3869–74.
- Arias F, Domínguez MA, Illarramendi JJ, et al. Split hiperfractionated accelerated radiation therapy and concomitant cisplatin for locally advanced head and neck carcinomas: A preliminary report. Int J Radiat Oncol. 1995;33:675–82. CrossRef
- Arias F, Vera R, Domínguez MA, et al. Hyperfractionated radiotherapy and concomitant cisplatin for locally advanced laryngeal and hypopharyngeal carcinomas: Final results of a Single-Institutional program. Am J Clin Oncol. 2003;26:550–7. CrossRef
- Ang KK, Harris J, Garden AS, et al. Concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas: Preliminary results of a phase II trial of the RTOG (99-14) [abstract]. Int J Radiat Oncol Biol Phys. 2002;54 (Supl 0):71. CrossRef
- Antonadou D, Pepelasi M, Synodinou M, et al. Prophylactic use of amifostin to prevent radiochemotherapy-induced mucositis and xerostomy in head and neck cancer. Int J Radiat Oncol Biol Phys. 2002;52:739–47. CrossRef
- Vokes EE, Pajak TF. Enhancing the therapeutic index of concomitant chemoradiotherapy for head and neck cancer. Ann Oncol. 1998;9:471–4. CrossRef
- Eisbruch A, Shewach D, Bradford C, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. JCO. 2001;19:792–9.
- Sunwoo J, Herscher L, Kroog G, et al. Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. J Clin Oncol. 2001;19:800–11.
- Robert F, Ezekiel M, Spencer S, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19:3234–43.
- Temam S, Flahaut A, Perie S, et al. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol. 2000; 18:385–90.
- Tanaka H, Arakawa H, Yamaguchi T, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 2000;404: 42–9. CrossRef
- Pruneri G, Pignataro L, Carboni N, et al. Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p51 and p27 in laryngeal cancer. J Clin Oncol. 1999;17: 3150–9.
- Veltmant JA, Bot FJ, Huynen FC, et al. Chromosome instability as an indicator of malignant progression in laryngeal mucosa. J Clin Oncol. 2000;18:1644–51.
- Falck J, Mailand N, Syljuasen R, et al. The ATM-Chk2-Cdc checkpoint parway guards against radioresistant DNA syntesis. Nature 2001;410:842–7. CrossRef
- Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76. CrossRef
- Bjordal K, Hammerlid E, Ahlner-Elmqvist M, et al. Quality of life in head and neck patients: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol. 1999;17:1008–19.
- Concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas. Preliminary results of a phase II, single-institutional trial
Clinical and Translational Oncology
Volume 7, Issue 2 , pp 60-65
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- head and neck cancer
- Industry Sectors
- Author Affiliations
- 1. Service of Radiation Oncology. Head and Neck Division, Hospital de Navarra, 3, Irunlarrea St., 51008, Pamplona, Spain
- 2. Service of Medical Oncology, Hospital de Navarra, Pamplona, Spain
- 3. Service of Otolaryngology, Hospital Virgen del Camino, Pamplona, Spain
- 4. Service of Nutrition, Hospital de Navarra, Pamplona, Spain